Sign Out
Caution should be exercised in the concomitant use of drugs known to interact with standard doxorubicin HCl. Like other doxorubicin HCl preparations, pegylated liposomal doxorubicin may potentiate the toxicity of other anti-cancer therapies.
Pegylated liposomal doxorubicin HCl has been administered to patients with solid tumors (including ovarian cancer or breast cancer) as part of combination therapy regimen (combined with either cyclophosphamide, taxanes or vinorelbine). In AIDS-KS patients, it has been reported that conventional doxorubicin HCl exacerbates the cyclophosphamide-induced hemorrhagic cystitis and enhances the hepatotoxicity of 6-mercaptopurine. Caution must be exercised when giving other cytotoxic agents, especially those may induce bone marrow suppression, at the same time.
